GB2150690A - Methods and test kit for diagnosing cancer in humans - Google Patents

Methods and test kit for diagnosing cancer in humans

Info

Publication number
GB2150690A
GB2150690A GB08430629A GB8430629A GB2150690A GB 2150690 A GB2150690 A GB 2150690A GB 08430629 A GB08430629 A GB 08430629A GB 8430629 A GB8430629 A GB 8430629A GB 2150690 A GB2150690 A GB 2150690A
Authority
GB
United Kingdom
Prior art keywords
level
urine
humans
methods
modified nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08430629A
Other versions
GB2150690B (en
GB8430629D0 (en
Inventor
Babara Schneider Vold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
Original Assignee
SRI International Inc
Stanford Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1983/000579 external-priority patent/WO1983003903A1/en
Priority claimed from US06/532,998 external-priority patent/US4665018A/en
Application filed by SRI International Inc, Stanford Research Institute filed Critical SRI International Inc
Publication of GB8430629D0 publication Critical patent/GB8430629D0/en
Publication of GB2150690A publication Critical patent/GB2150690A/en
Application granted granted Critical
Publication of GB2150690B publication Critical patent/GB2150690B/en
Expired legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Human cancer is diagnosed/monitored by measuring the levels of certain modified nucleosides, such as N-[9-( beta -D-ribofuranosyl)purin-6-ylcarbamoyl]-L-threonine, in the urine of a subject by a quantitative immunoassay that preferably employs a monoclonal anti-modified nucleoside antibody and comparing that level to the level of the modified nucleoside that occurs in the urine of normal subjects to determine whether the former is substantially elevated over the latter or by comparing that level to the level of the modified nucleoside present in urine specimens taken from the subject at different times.
GB08430629A 1983-04-18 1984-03-05 Methods and test kit for diagnosing cancer in humans Expired GB2150690B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1983/000579 WO1983003903A1 (en) 1982-04-23 1983-04-18 Methods and test kit for diagnosing cancer in humans
US06/532,998 US4665018A (en) 1983-04-18 1983-09-16 Methods and test kit for diagnosing/monitoring cancer in humans

Publications (3)

Publication Number Publication Date
GB8430629D0 GB8430629D0 (en) 1985-01-09
GB2150690A true GB2150690A (en) 1985-07-03
GB2150690B GB2150690B (en) 1987-07-01

Family

ID=24124035

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08430629A Expired GB2150690B (en) 1983-04-18 1984-03-05 Methods and test kit for diagnosing cancer in humans

Country Status (2)

Country Link
GB (1) GB2150690B (en)
SE (1) SE8406416D0 (en)

Also Published As

Publication number Publication date
SE8406416L (en) 1984-12-17
GB2150690B (en) 1987-07-01
SE8406416D0 (en) 1984-12-17
GB8430629D0 (en) 1985-01-09

Similar Documents

Publication Publication Date Title
Esplin et al. Thyroid autoantibodies are not associated with recurrent pregnancy loss
Arbesman et al. IgE levels in sera of patients with pemphigus or bullous pemphigoid
NO160746C (en) PROCEDURE FOR DETECTING OCCULT BLOOD IN FACES TESTS.
Hjiyiannakis et al. Thyroglobulin antibodies in differentiated thyroid cancer
DK0516746T3 (en) Oral collection for immunoassay
GERMAIN et al. Age‐related anti‐thyroid antibodies and thyroid abnormalities in Turner syndrome
ATE376187T1 (en) DETECTION OF DISEASES OF THE KIDNEYS AND TREATMENT
DK0483194T3 (en) IgG3 antibodies with shortened hinge region and a complement activation test
Paimela et al. Prognostic value of quantitative measurement of rheumatoid factor in early rheumatoid arthritis
CA2235316A1 (en) A method for detecting antipolymer antibodies and a diagnostic test kit for use in aiding the diagnosis of silicone related diseases (srd)
NO161287C (en) HOMOGENIC IMMUNOLOGICAL METHOD OF ANALYSIS, REAGENTS AND TESTING DEVICES FOR USE BY IMMUNO ANALYSIS DETERMINATION.
Bjøro et al. Thyroid antibodies in blood donors: prevalence and clinical significance
GB8901859D0 (en) Diagnostic test
Lilja et al. Prediction of atopic disease in infancy by determination of immunological parameters: IgE, IgE‐and IgG‐antibodies to food allergens, skin prick tests and T‐lymphocyte subsets
Lukens et al. Comparison of different immunoassays for the detection of antibodies against intrinsic factor and parietal cells
GB2150690A (en) Methods and test kit for diagnosing cancer in humans
EP1476757A4 (en) Method and kit for predicting cancer
GB2129934A (en) Methods and test kit for diagnosing cancer in humans
Centifanto et al. A simplified method for measuring human IgE
Vaira et al. Stool Test forHelicobacter Pylori
CA2409208A1 (en) Method for examining wt1-related disease
Sweeney et al. Advances in early fetal loss research: importance for risk assessment.
STADEN et al. Differential lectin reactivities of α‐fetoprotein in hepatocellular carcinoma: Diagnostic value when serum α‐fetoprotein levels are slightly raised
Chorzelski et al. Reliability of indirect immunofluorescence testing
DE3854603D1 (en) TEST STRIP FOR DIAGNOSIS BY MULTI-IMMUNOASSAY SYSTEM.

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19940305